Why study depression?

Major depression affects close to 2,000,000 Canadians annually and is the leading cause of time lost from work, more than cancer or heart disease. Depression is a risk factor for suicide, which in responsible for more than 3500 deaths annually in Canada. 

Depression can affect anyone, regardless of their age, ethnicity, and socioeconomic status. Many depression treatments exist, but there are no specific ways to match a treatment—medication, psychotherapy, or other treatment—to a person except through trial and error. As a result, it can be a long and difficult process to find the treatment for the right patient. 

CAN-BIND: The Canadian Biomarker Integration Network in Depression

  • The Canadian Biomarker Integration Network in Depression (CAN-BIND) aims to take the guess work out of psychiatric treatment for depression by finding clear and objective ways of matching the right treatment to the right patient for various types of depression. CAN-BIND aims to help reduce the impact of depression and its treatment by identifying “biomarkers”, which are biological and clinical characteristics that can help guide treatment selection.

    CAN-BIND is conducting a cross-Canada study of people being treated with different types of therapy for depression, such as drug therapy or transcranial magnetic stimulation (a non-invasive brain stimulation technique approved as a treatment for major depression). These people are also getting a variety of blood tests, questionnaires, and brain scans to determine if there are biomarkers that can predict treatment response in different types of patients. We fund the Ontario portion of CAN-BIND, which has a Canada-wide presence.

    visit CAN-BIND
  • CAN-BIND: The Canadian Biomarker Integration Network in Depression

    Play video